期刊文献+

三阴性乳腺癌的治疗现状及进展 被引量:24

Current treatment status and prospect of triple-negative breast cancer
在线阅读 下载PDF
导出
摘要 乳腺癌是女性常见的恶性肿瘤之一,居中国女性癌症发病首位,发病率和死亡率均呈上升趋势。三阴性乳腺癌(TNBC)是一种异质性疾病,较其他分型的乳腺癌具有发病年龄低,侵袭性强,复发和转移早的特点,目前尚缺乏标准治疗手段,疗效不佳,预后差,严重影响患者身心健康。文章总结和梳理TNBC的治疗现状和研究进展,以便提高对疾病的认识和治疗规范化水平。 Breast cancer is one of the most common female malignancies in China.The morbidity and mortality rate of breast cancer is rising.Triple-negative breast cancer(TNBC)is a heterogeneous disease,characterized with younger,more aggressive and easier recurrence or metastasis.Because there is no standard therapeutic regimen,TNBC has poor efficacy and prognosis,and seriously affects the patients′health.Summarizing and combing the status and progress of TNBC treatment can help us to better understand the disease and improve treatment.In addition,it inspires us to form new research ideas and explore the research directions of TNBC.
作者 周洁 陈萱 陈钰 陈道桢 ZHOU Jie;CHEN Xuan;CHEN Yu;CHEN Dao-zhen(Department of Central Laboratory,Wuxi Hospital for Maternal and Child Health Care Affiliated to Nanjing Medical University,Wuxi 214002,Jiangsu,China;Kangda College of Nanjing Medical University,Lianyungang 222023,Jiangsu,China)
出处 《医学研究生学报》 CAS 北大核心 2018年第8期853-858,共6页 Journal of Medical Postgraduates
基金 国家自然科学基金(81372480 81602728) 江苏省大学生创新创业训练计划项目(201713980001Y)
关键词 三阴性乳腺癌 化疗 靶向治疗 免疫治疗 内分泌治疗 triple-negative breast cancer chemotherapy targeted therapy immunotherapy endocrine therapy
作者简介 通信作者:陈道桢,E-mail:chendaozhen@163.com。
  • 相关文献

参考文献2

二级参考文献40

  • 1于泽平,李幼生,王少华,罗开,顾军,李民,祁正茂,季红爱.细针穿刺吸取细胞学检查对乳腺癌的诊断价值[J].医学研究生学报,2006,19(5):474-475. 被引量:25
  • 2Fisher B, Bryant J, Welmark N, et al. Effect of preoperative chem- otherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowl Project B-18 [J]. J Clin Oncol, 1997,15 (7) :2488-2492.
  • 3Jones RL, Smith IE. Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumor response [ J ]. Lancet Oncot, 2006,7(10) :869-874.
  • 4Berry DA, Cirrincione C, Hederson IC, et al. Estrogen-recep-tor status and outcomes of modern chemotherapy for patients with node-positive breast cancer [ J ]. JAMA, 2006,295 ( 14 ) : 1658- 1667.
  • 5Guarneri V, Broglio K, Kau SW, et al. Prognostic value pathologic complete response after primary chemotheraphy in relation to hor- mone receptor status and other factors[ J]. J Clin Onco1,2006,24 (7) : 1037-1044.
  • 6Faneyte IF, Schrama JG, Peters JL, et al. Breast cancer response to neoadjuvant chemotherapy : predictive markers and relation with outcome[J]. Br J Cancer,2003,88 ( 3 ) :406-412.
  • 7Eifel P, Axelson JA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 123,2000 [J]. Natl Cancer Inst, 2001,93 ( 13 ) :979-989.
  • 8Slamon D J, Clark GM, Wang SG, et al. Human breast cancer: cor- relation of relapse and survival with amplification of the HER-2/ neu oncogene[J]. Science, 1987,235 (4785) : 177-182.
  • 9Tsutsui S, Ohno S, Murakami S,et al. Prognostic value of Cerb- 2 expression in breast cancer[J]. J Surg Oncol,2002,79 (4) : 216-223.
  • 10Van de Vijver MJ. Assessment of the need and appropriate meth- od for testing for the human epidermal growth factor receptor-2 ( HER-2 ) [ J ]. Eur J Cancer,2001,37 ( Suppll ) : S11-S17.

共引文献16

同被引文献184

引证文献24

二级引证文献125

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部